[Long-term follow-up of ofloxacin-combined therapy for leprosy patients].
This reports a long-term follow-up study on clinical effects of ofloxacin (OFLX)-combined therapy to 14 leprosy patients with various types and stages. Combined drugs were diaminodiphenyl sulfone (DDS), rifampicin (RFP) and clofazimine. Clinical evaluation of the treatment after OFLX-combined therapy was remarkable improvement 10 cases, improvement 3 and re-exacerbated after improvement 1 to whom clofazimine and minocycline were prescribed. The evaluation during the follow-up was remarkable improvement 10, improvement 1; three cases died of traffic accident or complications not related to chemotherapy and none of them showed relapse of leprosy. Bacterial negativity after onset of OFLX-combined therapy was achieved in about the same periods as RFP-combined therapy. OFLX-combined therapy was effective and safe. This follow-up study supports the efficacy of clinical guideline for the use of new quinolones published by Japanese leprosy Association.
Ozaki
Motoaki
M
Nagashima Aisei-en National Leprosarium, Okayama, Japan. mozak@aiseien.hosp.go.jp
Ishikawa
Makiko
M
D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002991:Clofazimine / Q000008:administration & dosage; D003538:Cystamine / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D007917:Leprostatic Agents / Q000008:administration & dosage; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage; D015242:Ofloxacin / Q000008:administration & dosage*; D012293:Rifampin / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D007917:Leprostatic Agents; D015242:Ofloxacin; D002991:Clofazimine; D008911:Minocycline; D003538:Cystamine; D012293:Rifampin